title: Pamidronate (Aredia, Ciba).
abstract: Pamidronate disodium appears beneficial in relieving metastatic bone pain refractory to NSAIDS and steroids. However, due to the invasiveness of administration and costs associated with the infusion, it should not be considered first line therapy. On the other hand, potential cost savings over conventional radiation therapy or surgery to relieve bone pain could make pamidronate a very attractive option.
authors.affiliation: University of Maryland, Baltimore, USA.
authors.forename: K M
authors.initials: KM
authors.lastname: Strong
authors.forename: M L
authors.initials: ML
authors.lastname: McPherson
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000150:complications / Q000188:drug therapy*; D002648:Child; D004164:Diphosphonates / Q000627:therapeutic use*; D006801:Humans; D006934:Hypercalcemia / Q000188:drug therapy* / Q000209:etiology; D010001:Osteitis Deformans / Q000188:drug therapy*; D000077268:Pamidronate; D013727:Terminal Care
chemical_list: D000970:Antineoplastic Agents; D004164:Diphosphonates; D000077268:Pamidronate